A cross-structural analysis published in Mayo Clinic Proceedings this January independently links diabetes to the development of heart failure, suggesting diabetic cardiomyopathy is a real—and growing—issue in the U.S.

Drugmaker AstraZeneca announced Jan. 6 that its SGLT2 inhibitor dapagliflozin, sold commercially as Farxiga, had been granted Priority Review by the FDA for patients with heart failure with reduced ejection fraction.

Diagnosed cases of chronic heart failure are expected to number 32 million by 2028, according to a report from analytics company GlobalData.

Beta-blocker use was linked to an increased risk of heart failure hospitalizations in a recent study of patients with “stiff heart” HF—a concerning finding considering the majority of such patients take the drugs as part of their care regimen.

Novoheart, a Vancouver-based stem cell biotech company, is pairing with biopharmaceutical giant AstraZeneca to develop the world’s first human-specific in vitro functional model of heart failure with preserved ejection fraction.

Brushing teeth three or more times a day could dramatically lower a person’s risk for CVDs like heart failure and atrial fibrillation, according to preliminary research out of Ewha Womans University in Seoul, South Korea.

Use of the Impella heart pump during PCI rose rapidly between the 2000s and 2010s, according to a Circulation analysis—but so did its variability across hospitals and associated adverse outcomes.

The FDA has granted Breakthrough Device status to BioVentrix, Inc.’s Revivent TC Transcatheter Ventricular Enhancement System, a proactive approach to treating MI-induced heart failure.

A novel pacemaker designed to mimic a patient’s organic breath increased blood flow to the heart in a study of individuals with heart failure, according to research published in the journal Thorax.

Patients with heart failure and reduced ejection fraction are well served by treatment with the glucose-lowering drug dapagliflozin, as it warded off death and hospitalization while also improving quality of life when added to standard care regimens in a major trial.

A collaboration between physicists and cardiologists at the University of California San Diego has resulted in an AI tool that can predict heart failure patients’ life expectancy with 88% accuracy.

Results from the world’s largest comprehensive study of hypertrophic cardiomyopathy patients are in—and they’re providing cardiologists with a wealth of previously unknown information about the disease.